Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter 2020 Financial Results on July 30, 2020

Rhea-AI Summary

Corvus Pharmaceuticals (NASDAQ: CRVS) announced a conference call on July 30, 2020, at 4:30 pm ET to discuss its business update and second quarter 2020 financial results. The call can be accessed via a toll-free number or by webcast through the investor relations section of their website. Corvus is a clinical-stage biopharmaceutical firm focused on cancer therapies, with key products including ciforadenant, CPI-006, and CPI-818 currently in various clinical trials, including studies for COVID-19 treatment.

Positive

• Ongoing Phase 1b/2 trials for ciforadenant and CPI-006 targeting advanced solid tumors.
• CPI-818 in Phase 1/1b clinical trials for T-cell lymphomas.

Negative

• None.

BURLINGAME, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and webcast on July 30, 2020 at 4:30 pm ET (1:30 pm PT) to provide a business update and report second quarter 2020 financial results. 

The conference call can be accessed by dialing 1-855-327-6837 (toll-free domestic) or 1-631-891-4304 (international) and using the conference ID 10010533. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus' website for 90 days.

About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company. Corvus’ lead product candidates are ciforadenant (CPI-444), a small molecule inhibitor of the A2A receptor, and CPI-006, a humanized monoclonal antibody directed against CD73 that exhibits immunomodulatory activity and activation of immune cells. These product candidates are being studied in ongoing Phase 1b/2 and Phase 1/1b clinical trials in patients with a wide range of advanced solid tumors. Ciforadenant is being evaluated in a successive expansion cohort Phase 1b/2 trial examining its activity both as a single agent and in combination with an anti-PD-L1 antibody. CPI-006 is being evaluated in a multicenter Phase 1/1b clinical trial as a single agent, in combination with ciforadenant and pembrolizumab. The Company’s third cancer clinical program, CPI-818, an oral, small molecule drug that has been shown to selectively inhibit ITK, is in a multicenter Phase 1/1b clinical trial in patients with several types of T-cell lymphomas. The Company is also evaluating CPI-006 as a treatment for COVID-19 patients.  For more information, visit www.corvuspharma.com.

INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
650-900-4522
LLea@corvuspharma.com

MEDIA CONTACT:
Sheryl Seapy
W2O pure
+1 213-262-9390
sseapy@purecommunications.com

FAQ

What is the purpose of Corvus Pharmaceuticals' conference call on July 30, 2020?

The conference call is to provide a business update and report second quarter 2020 financial results.

How can I access the Corvus Pharmaceuticals conference call?

You can access the conference call by dialing a toll-free number or through the live webcast on Corvus' investor relations website.

What are the key product candidates of Corvus Pharmaceuticals?

Corvus' key candidates include ciforadenant, CPI-006, and CPI-818, which are in various stages of clinical trials.